| Date | Time | Source | |
| 06/05/2013 | 9:45AM | GLOBE | Nymox to Present at Jefferies 2013 Healthcare Conference in New York City on June 6
HASBROUCK HEIGHTS, N.J., June 5, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that Paul Averback, MD, DABP, President and Chief Executive Officer of Nymox, will be providing a corporate summary and presentation regarding the Company's ongoing clinical program for NX-1207 at the... More...>> |
| 05/15/2013 | 9:45AM | GLOBE | Nymox Reports First Quarter 2013 Financial Results
HASBROUCK HEIGHTS, N.J., May 15, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the first quarter of 2013. Nymox reported a net loss of $1,093,906, or $0.03 per share for the quarter ended March 31, 2013, compared to $1,846,974, or $0.06 per share for the... More...>> |
| 05/06/2013 | 9:00AM | GLOBE | Nymox Reports on Symposium and Panel Discussion on NX-1207 at American Urological Association Annual Meeting
HASBROUCK HEIGHTS, N.J., May 6, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report on the presentation on NX-1207 drug studies at a high-level symposium and panel discussion held at the Annual Meeting of the American Urological Association in San Diego, CA between 3:00 and 4:00... More...>> |
| 05/03/2013 | 11:47AM | GLOBE | Nymox Announces Completion of Patient Enrollment in Final Pivotal U.S. Phase 3 BPH Study
HASBROUCK HEIGHTS, N.J., May 3, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today completion of patient enrollment in the Company's final pivotal U.S. Phase 3 NX02-0018 Study of NX-1207 for BPH. This study is now closed to further enrollment. Top-line results from the large Phase 3... More...>> |
| 04/30/2013 | 11:02AM | GLOBE | Nymox NX-1207 Symposium May 5 in San Diego at Annual Meeting of American Urological Association at San Diego Convention Center
HASBROUCK HEIGHTS, N.J., April 30, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce further information about the upcoming Symposium on NX-1207 to be held on May 5 at 3 p.m. in San Diego at the Annual Meeting of the American Urological Association at the San Diego Convention... More...>> |
| 04/23/2013 | 12:00PM | GLOBE | Nymox Announces First Patient Enrollment for NX02-0022 Reinjection Study of NX-1207 for BPH
HASBROUCK HEIGHTS, N.J., April 23, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that the first patient has been enrolled in the Company's Study NX02-0022. The NX02-0022 Study is designed as an open label study of the safety and efficacy of NX-1207 reinjection for the treatment... More...>> |
| 04/16/2013 | 10:32AM | GLOBE | New Study Supports Favorable Sexual Function Profile for Nymox's NX-1207 for Prostate Enlargement
HASBROUCK HEIGHTS, N.J., April 16, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported today positive new study findings which have demonstrated that the Company's NX-1207 Phase 3 treatment for benign prostatic hyperplasia (BPH or prostatic enlargement) has no detectable effect on key male... More...>> |
| 04/11/2013 | 9:50AM | GLOBE | Nymox NX-1207 BPH and Prostate Cancer Symposium at American Urological Association Annual Meeting May 5 in San Diego
HASBROUCK HEIGHTS, N.J., April 11, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce an important upcoming symposium and panel discussion on its first-in-class investigational drug NX-1207, currently in late stage Phase 3 for benign prostatic hyperplasia (BPH) and Phase 2 for... More...>> |
| 04/02/2013 | 5:00PM | GLOBE | Press Release Issued Under the Early Warning System/Sale of Shares of Nymox Pharmaceutical Corporation
MONTREAL, April 2, 2013 (GLOBE NEWSWIRE) -- This press release is being disseminated as required by the early warning requirements of applicable Canadian securities laws. Paul Averback MD of 9900 Cavendish Blvd. Suite 306, St-Laurent, Quebec, announces today that he has sold in a private transaction for financial planning... More...>> |
| 03/27/2013 | 11:00AM | GLOBE | Nymox's NicAlert(TM) Has Achieved Widespread Acceptance in Tobacco-Related Research Studies
HASBROUCK HEIGHTS, N.J., March 27, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported today that the Company's FDA Cleared NicAlert™ product continues to achieve widespread acceptance around the world as an important tool in tobacco-related research studies and programs in a broad range... More...>> |
| 03/21/2013 | 2:25PM | ZACKS | Good News for Nymox's Pipeline - Analyst Blog
Positive news flowed in at Nymox Pharmaceutical Corporation (NYMX) recently when the Independent Data Monitoring Committee (IDMC) reported the third positive analysis of safety data from the company’s ongoing phase II study (NX03-0040) of NX-1207 for low grade localized prostate cancer. The IDMC’s interim... More...>> |
| 03/19/2013 | 10:00AM | GLOBE | Nymox Prostate Cancer Trial Receives Positive Interim Safety Review From Independent Data Monitoring Committee
HASBROUCK HEIGHTS, N.J., March 19, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced that the Independent Data Monitoring Committee for the Company's Phase 2 study of NX-1207 for low risk localized prostate cancer (NX03-0040) has reported a third positive analysis of safety data from... More...>> |
| 03/18/2013 | 9:31AM | GLOBE | Nymox Announces Presentation of NX-1207 Data at Annual Meeting of the European Association of Urology
HASBROUCK HEIGHTS, N.J., March 18, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report on the presentation of data on NX-1207, the Company's novel patented drug, at the European Association of Urology's annual meeting held in Milan, Italy. NX-1207 is currently in Phase 3 trials... More...>> |
| 03/15/2013 | 11:30AM | GLOBE | Nymox Announces Upcoming Presentation of NX-1207 Data at European Association of Urology Congress
HASBROUCK HEIGHTS, N.J., March 15, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that a presentation entitled "Clinical studies of NX-1207: Phase 3 Injectable for BPH" will be given at 3:45 p.m. March 17 during the 28th Annual European Association of Urology Congress in the Milano... More...>> |
| 03/15/2013 | 9:45AM | GLOBE | Nymox Reports 2012 Financial Results
HASBROUCK HEIGHTS, N.J., March 15, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the year ended December 31, 2012 prepared in accordance with International Financial Reporting Standards. Nymox reported a net loss of $7,627,589, or $0.23 per share for the... More...>> |
| 03/05/2013 | 11:19AM | GLOBE | Nymox Provides Current Phase 2 Prostate Cancer Clinical Trial Update
HASBROUCK HEIGHTS, N.J., March 5, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today provided an update on U.S. Phase 2 prostate cancer clinical trial activities for NX-1207, the company's new investigational drug being tested for early stage prostate cancer. The prostate cancer trial has reached... More...>> |
| 03/01/2013 | 1:43PM | GLOBE | Nymox Says No Material Information or News in Relation to Unusual Market Activity
HASBROUCK HEIGHTS, N.J., March 1, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) advises that the company is not aware of any undisclosed material information or news that would account for the unusual market activity in the trading of the company's securities on the Nasdaq exchange. More information... More...>> |
| 02/21/2013 | 10:30AM | GLOBE | Favorable February 18 Safety Monitoring Committee Meeting for Nymox Pivotal Phase 3 NX-1207 Trials
HASBROUCK HEIGHTS, N.J., Feb. 21, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) provided an update today on the Company's Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of February 18, 2013 to review... More...>> |
| 02/19/2013 | 10:15AM | GLOBE | Nymox Announces Positive Immunogenicity Results for NX-1207 BPH Program
HASBROUCK HEIGHTS, N.J., Feb. 19, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce its lead drug candidate, NX-1207, has not shown any evidence of eliciting an immune reaction in men treated with intraprostatic injections of the drug. Extensive clinical immunogenicity testing... More...>> |
| 02/06/2013 | 10:30AM | GLOBE | Nymox to Present at the 15th Annual BIO CEO & Investor Conference
HASBROUCK HEIGHTS, N.J., Feb. 6, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that CEO Paul Averback will be presenting at the 15th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 15th Annual BIO CEO & Investor Conference will... More...>> |
